Arellano, M., and Moreno, S. (1997). Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 29, 559-573.
Baselga, J., and Albanell, J. (2001). Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl 1, S35-41.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14, 737-744.
Beerli, R. R., Segal, D. J., Dreier, B., and Barbas, C. F., 3rd (1998). Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 95, 14628-14633.
Bellosillo, B., Dalmau, M., Colomer, D., and Gil, J. (1997). Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 89, 3378-3384.
Bode, A. M., and Dong, Z. (2007). The functional contrariety of JNK. Molecular carcinogenesis 46, 591-598.
Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991). ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675.
Brachmann, S. M., Yballe, C. M., Innocenti, M., Deane, J. A., Fruman, D. A., Thomas, S. M., and Cantley, L. C. (2005). Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Molecular and cellular biology 25, 2593-2606.
Brinkman, J. A., and El-Ashry, D. (2009). ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 14, 67-78.
Cain, K. (2003). Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab Rev 35, 337-363.
Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., et al. (2005). Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23, 5007-5018.
Carpenter, G., Lembach, K. J., Morrison, M. M., and Cohen, S. (1975). Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. The Journal of biological chemistry 250, 4297-4304.
Chan, E. D., and Riches, D. W. (2001). IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 280, C441-450.
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., and McCubrey, J. A. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603.
Chevrollier, A., Loiseau, D., Gautier, F., Malthiery, Y., and Stepien, G. (2005). ANT2 expression under hypoxic conditions produces opposite cell-cycle behavior in 143B and HepG2 cancer cells. Mol Carcinog 42, 1-8.
Chiang, C. T., Way, T. D., and Lin, J. K. (2007). Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther 6, 2127-2138.
Chiang, S. Y., Burli, R. W., Benz, C. C., Gawron, L., Scott, G. K., Dervan, P. B., and Beerman, T. A. (2000). Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J Biol Chem 275, 24246-24254.
Chuang, T. C., Yu, Y. H., Lin, Y. S., Wang, S. S., and Kao, M. C. (2002). The N-terminal domain of SV40 large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers. FEBS Lett 511, 46-50.
Chung, Y. L., Sheu, M. L., Yang, S. C., Lin, C. H., and Yen, S. H. (2002). Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97, 306-312.
Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8, 459-465.
Curtin, J. F., Donovan, M., and Cotter, T. G. (2002). Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 265, 49-72.
Darragh, J., Soloaga, A., Beardmore, V. A., Wingate, A. D., Wiggin, G. R., Peggie, M., and Arthur, J. S. (2005). MSKs are required for the transcription of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling. Biochem J 390, 749-759.
Deak, M., Clifton, A. D., Lucocq, L. M., and Alessi, D. R. (1998). Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17, 4426-4441.
Deveraux, Q. L., and Reed, J. C. (1999). IAP family proteins--suppressors of apoptosis. Genes Dev 13, 239-252.
Disis, M. L., and Schiffman, K. (2001). Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28, 12-20.
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., and Greene, M. I. (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706.
Ekedahl, J., Joseph, B., Grigoriev, M. Y., Muller, M., Magnusson, C., Lewensohn, R., and Zhivotovsky, B. (2002). Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 279, 277-290.
Eskes, R., Desagher, S., Antonsson, B., and Martinou, J. C. (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20, 929-935.
Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., and Hunt, T. (1983). Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33, 389-396.
Fisher, R. P. (1994). A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78, 713-724.
Folmer, F., Blasius, R., Morceau, F., Tabudravu, J., Dicato, M., Jaspars, M., and Diederich, M. (2006). Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem Pharmacol 71, 1206-1218.
Fujimoto, N., Wislez, M., Zhang, J., Iwanaga, K., Dackor, J., Hanna, A. E., Kalyankrishna, S., Cody, D. D., Price, R. E., Sato, M., et al. (2005). High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65, 11478-11485.
Fukunaga, R., and Hunter, T. (1997). MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16, 1921-1933.
Gao, N., Flynn, D. C., Zhang, Z., Zhong, X. S., Walker, V., Liu, K. J., Shi, X., and Jiang, B. H. (2004). G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287, C281-291.
Geethangili, M., and Tzeng, Y. M. (2009). Review of Pharmacological Effects of Antrodia camphorata and its Bioactive Compounds. Evid Based Complement Alternat Med.
Girard, F., Strausfeld, U., Fernandez, A., and Lamb, N. J. (1991). Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67, 1169-1179.
Grunt Th, W., Dittrich, E., Offterdinger, M., Schneider, S. M., Dittrich, C., and Huber, H. (1998). Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78, 79-87.
Harper, J. V. (2005). Synchronization of cell populations in G1/S and G2/M phases of the cell cycle. Methods Mol Biol 296, 157-166.
Hartwell, L. H., and Weinert, T. A. (1989). Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629-634.
Haynes, N. M., Smyth, M. J., Kershaw, M. H., Trapani, J. A., and Darcy, P. K. (1999). Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunol Immunother 47, 278-286.
Hermanto, U., Zong, C. S., and Wang, L. H. (2001). ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20, 7551-7562.
Hisahara, S., Takano, R., Shoji, S., Okano, H., and Miura, M. (2000). Role of caspase-1 subfamily in cytotoxic cytokine-induced oligodendrocyte cell death. J Neural Transm Suppl, 135-142.
Ho, P. K., and Hawkins, C. J. (2005). Mammalian initiator apoptotic caspases. FEBS J 272, 5436-5453.
Hong, R. L., Spohn, W. H., and Hung, M. C. (1999). Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5, 1884-1891.
Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., et al. (2001). Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19, 3422-3433.
Hseu, Y. C., Chang, W. C., Hseu, Y. T., Lee, C. Y., Yech, Y. J., Chen, P. C., Chen, J. Y., and Yang, H. L. (2002). Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci 71, 469-482.
Hseu, Y. C., Chen, S. C., Chen, H. C., Liao, J. W., and Yang, H. L. (2008). Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Food Chem Toxicol 46, 2680-2688.
Hseu, Y. C., Chen, S. C., Tsai, P. C., Chen, C. S., Lu, F. J., Chang, N. W., and Yang, H. L. (2007). Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorata. Food Chem Toxicol 45, 1107-1115.
Hsieh, Y. C., Rao, Y. K., Wu, C. C., Huang, C. Y., Geethangili, M., Hsu, S. L., and Tzeng, Y. M. Methyl Antcinate A from Antrodia camphorata Induces Apoptosis in Human Liver Cancer Cells through Oxidant-Mediated Cofilin- and Bax-Triggered Mitochondrial Pathway. Chem Res Toxicol.
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9, 1165-1172.
Hurst, H. C. (2001). Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 3, 395-398.
Hynes, N. E., and Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews 5, 341-354.
Im, S. A., Lee, K. E., Nam, E., Kim, D. Y., Lee, J. H., Han, H. S., Seoh, J. Y., Park, H. Y., Cho, M. S., Han, W. S., and Lee, S. N. (2005). Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 91, 513-521.
Jeong, J. H., An, J. Y., Kwon, Y. T., Li, L. Y., and Lee, Y. J. (2008). Quercetin-induced ubiquitination and down-regulation of Her-2/neu. Journal of cellular biochemistry 105, 585-595.
Jeong, S. J., Pise-Masison, C. A., Radonovich, M. F., Park, H. U., and Brady, J. N. (2005). Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24, 6719-6728.
Jimenez, C., Jones, D. R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S., von Kobbe, C., Toran, J. L., L, R. B., Calvo, V., et al. (1998). Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17, 743-753.
Jung, Y., Xu, W., Kim, H., Ha, N., and Neckers, L. (2007). Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 1773, 383-390.
Kallergi, G., Agelaki, S., Kalykaki, A., Stournaras, C., Mavroudis, D., and Georgoulias, V. (2008). Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10, R80.
Kao, M. C., Law, S. L., Chuang, T. C., and Lin, Y. S. (1998). In vitro gene transfer in mammalian cells via a new cationic liposome formulation. Oncol Rep 5, 625-629.
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17, 615-675.
Kerr, J. F., Winterford, C. M., and Harmon, B. V. (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026.
King, R. W., Jackson, P. K., and Kirschner, M. W. (1994). Mitosis in transition. Cell 79, 563-571.
Kluck, R. M., Martin, S. J., Hoffman, B. M., Zhou, J. S., Green, D. R., and Newmeyer, D. D. (1997). Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J 16, 4639-4649.
Kyriakis, J. M., and Avruch, J. (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81, 807-869.
Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., and Hauser, C. (1995). Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398.
Lee, S. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, K. Y., Kim, S. H., Lee, J. Y., and Yoo, N. J. (2002). Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110, 587-592.
Lenferink, A. E., Busse, D., Flanagan, W. M., Yakes, F. M., and Arteaga, C. L. (2001). ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61, 6583-6591.
Li, F., Srinivasan, A., Wang, Y., Armstrong, R. C., Tomaselli, K. J., and Fritz, L. C. (1997). Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 272, 30299-30305.
Lyu, M. A., and Rosenblum, M. G. (2005). The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther 4, 1205-1213.
Maizels, E. T., Mukherjee, A., Sithanandam, G., Peters, C. A., Cottom, J., Mayo, K. E., and Hunzicker-Dunn, M. (2001). Developmental regulation of mitogen-activated protein kinase-activated kinases-2 and -3 (MAPKAPK-2/-3) in vivo during corpus luteum formation in the rat. Mol Endocrinol 15, 716-733.
Matin, A., and Hung, M. C. (1993). Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ 4, 1051-1056.
McEleny, K. R., Watson, R. W., Coffey, R. N., O''Neill, A. J., and Fitzpatrick, J. M. (2002). Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 51, 133-140.
Menendez, J. A., Vellon, L., Colomer, R., and Lupu, R. (2005). Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol 16, 359-371.
Meyer, D., and Birchmeier, C. (1995). Multiple essential functions of neuregulin in development. Nature 378, 386-390.
Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., and Yuan, J. (2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403, 98-103.
Norbury, C., and Nurse, P. (1992). Animal cell cycles and their control. Annu Rev Biochem 61, 441-470.
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., and Pagano, M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15, 2612-2624.
Olson, J. M., and Hallahan, A. R. (2004). p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10, 125-129.
Oltmanns, U., Issa, R., Sukkar, M. B., John, M., and Chung, K. F. (2003). Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 139, 1228-1234.
Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., Chien, K. R., Birchmeier, C., and Garratt, A. N. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99, 8880-8885.
Parada-Turska, J., Paduch, R., Majdan, M., Kandefer-Szerszen, M., and Rzeski, W. (2007). Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 59, 233-237.
Patil, C., Zhu, X., Rossa, C., Jr., Kim, Y. J., and Kirkwood, K. L. (2004). p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest 33, 213-233.
Patwardhan, B., Warude, D., Pushpangadan, P., and Bhatt, N. (2005). Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med 2, 465-473.
Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J., and Phillips, W. A. (2001). The phosphatidylinositol 3''-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer research 61, 7426-7429.
Rao, G. N., Ney, E., and Herbert, R. A. (1999). Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Breast Cancer Res Treat 58, 241-254.
Rebischung, C., Barnoud, R., Stefani, L., Faucheron, J. L., and Mousseau, M. (2005). The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8, 249-252.
Reed, J. C. (1997). Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34, 9-19.
Robertson, M. J., Manley, T. J., Pichert, G., Cameron, C., Cochran, K. J., Levine, H., and Ritz, J. (1995). Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17, 51-61.
Rodemann, H. P., Dittmann, K., and Toulany, M. (2007). Radiation-induced EGFR-signaling and control of DNA-damage repair. International journal of radiation biology 83, 781-791.
Roh, H., Pippin, J., Boswell, C., and Drebin, J. A. (1998). Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res 77, 85-90.
Ross, J. S., and Fletcher, J. A. (1999). HER-2/neu (c-erb-B2) gene and protein in breast cancer. American journal of clinical pathology 112, S53-67.
Rosty, C., Couturier, J., Vincent-Salomon, A., Genin, P., Freneaux, P., Sigal-Zafrani, B., and Sastre-Garau, X. (2004). Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 23, 13-17.
Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Critical reviews in oncology/hematology 19, 183-232.
Salvesen, G. S., and Dixit, V. M. (1999). Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A 96, 10964-10967.
Schlessinger, J. (2002). Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669-672.
Schneider, P. M., Hung, M. C., Chiocca, S. M., Manning, J., Zhao, X. Y., Fang, K., and Roth, J. A. (1989). Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49, 4968-4971.
Schulze, W. X., Deng, L., and Mann, M. (2005). Phosphotyrosine interactome of the ErbB-receptor kinase family. Molecular systems biology 1, 2005 0008.
Schwartz, D., and Rotter, V. (1998). p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 8, 325-336.
Schwartzman, R. A., and Cidlowski, J. A. (1994). Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol 105, 347-354.
Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., and Gray, J. W. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99-102.
Sherr, C. J. (1994). G1 phase progression: cycling on cue. Cell 79, 551-555.
Shih, C., Padhy, L. C., Murray, M., and Weinberg, R. A. (1981). Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261-264.
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792.
Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26, 60-70.
Smith, P. J., Wiltshire, M., Chin, S. F., Rabbitts, P., and Soues, S. (1999). Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells. Int J Radiat Biol 75, 1137-1147.
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., and Rosen, N. (2003). Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer research 63, 2139-2144.
Souglakos, J., Vamvakas, L., Apostolaki, S., Perraki, M., Saridaki, Z., Kazakou, I., Pallis, A., Kouroussis, C., Androulakis, N., Kalbakis, K., et al. (2006). Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res 8, R36.
Sturgill, T. W., and Ray, L. B. (1986). Muscle proteins related to microtubule associated protein-2 are substrates for an insulin-stimulatable kinase. Biochem Biophys Res Commun 134, 565-571.
Suen, T. C., and Hung, M. C. (1991). c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol Cell Biol 11, 354-362.
Suh, Y. J., Chada, S., McKenzie, T., Liu, Y., Swisher, S. G., Lucci, A., and Hunt, K. K. (2005). Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery 138, 422-430.
Susin, S. A., Zamzami, N., and Kroemer, G. (1998). Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366, 151-165.
Tyson, F. L., Boyer, C. M., Kaufman, R., O''Briant, K., Cram, G., Crews, J. R., Soper, J. T., Daly, L., Fowler, W. C., Jr., Haskill, J. S., and et al. (1991). Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. American journal of obstetrics and gynecology 165, 640-646.
Tzahar, E., and Yarden, Y. (1998). The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochimica et biophysica acta 1377, M25-37.
Vanhaesebroeck, B., and Waterfield, M. D. (1999). Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253, 239-254.
Vermeulen, K., Van Bockstaele, D. R., and Berneman, Z. N. (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-149.
Vernimmen, D., Gueders, M., Pisvin, S., Delvenne, P., and Winkler, R. (2003). Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. British journal of cancer 89, 899-906.
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D''Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8, 1136-1144.
Vijayanathan, V., Thomas, T., Sigal, L. H., and Thomas, T. J. (2002). Direct measurement of the association constant of HER2/neu antisense oligonucleotide to its target RNA sequence using a molecular beacon. Antisense Nucleic Acid Drug Dev 12, 225-233.
Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
Vlahopoulos, S., and Zoumpourlis, V. C. (2004). JNK: a key modulator of intracellular signaling. Biochemistry (Mosc) 69, 844-854.
Waetzig, V., and Herdegen, T. (2005). Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 26, 455-461.
Walker, D. H., and Maller, J. L. (1991). Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354, 314-317.
Ward, S. G., and Finan, P. (2003). Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3, 426-434.
Way, T. D., Kao, M. C., and Lin, J. K. (2004). Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 279, 4479-4489.
Weiner, D. B., Nordberg, J., Robinson, R., Nowell, P. C., Gazdar, A., Greene, M. I., Williams, W. V., Cohen, J. A., and Kern, J. A. (1990). Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50, 421-425.
Wright, C. W., and Duckett, C. S. (2005). Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 115, 2673-2678.
Xia, Z., Lundgren, B., Bergstrand, A., DePierre, J. W., and Nassberger, L. (1999). Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol 57, 1199-1208.
Yang, G., Cai, K. Q., Thompson-Lanza, J. A., Bast, R. C., Jr., and Liu, J. (2004). Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. The Journal of biological chemistry 279, 4339-4345.
Yang, H. L., Chen, C. S., Chang, W. H., Lu, F. J., Lai, Y. C., Chen, C. C., Hseu, T. H., Kuo, C. T., and Hseu, Y. C. (2006). Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata. Cancer Lett 231, 215-227.
Yang, H. Y., Zhou, B. P., Hung, M. C., and Lee, M. H. (2000). Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275, 24735-24739.
Yang, J., Wu, L. J., Tashiro, S., Onodera, S., and Ikejima, T. (2008). Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic Res 42, 1-11.
Yokota, J., Yamamoto, T., Miyajima, N., Toyoshima, K., Nomura, N., Sakamoto, H., Yoshida, T., Terada, M., and Sugimura, T. (1988). Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2, 283-287.
Yu, C., Minemoto, Y., Zhang, J., Liu, J., Tang, F., Bui, T. N., Xiang, J., and Lin, A. (2004). JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 13, 329-340.
Yu, D., Suen, T. C., Yan, D. H., Chang, L. S., and Hung, M. C. (1990). Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 87, 4499-4503.
Zarich, N., Oliva, J. L., Martinez, N., Jorge, R., Ballester, A., Gutierrez-Eisman, S., Garcia-Vargas, S., and Rojas, J. M. (2006). Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1. Mol Biol Cell 17, 3591-3597.
Zarubin, T., and Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell Res 15, 11-18.
Zhang, L., Chang, C. J., Bacus, S. S., and Hung, M. C. (1995). Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 55, 3890-3896.
Zhang, L., and Hung, M. C. (1996). Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12, 571-576.
Zhang, L., Lau, Y. K., Xia, W., Hortobagyi, G. N., and Hung, M. C. (1999). Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5, 343-353.
Zhang, X., Hu, L., Fadeel, B., and Ernberg, I. T. (2002). Apoptosis modulation of Epstein-Barr virus-encoded latent membrane protein 1 in the epithelial cell line HeLa is stimulus-dependent. Virology 304, 330-341.
Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405-413.
高銘欽、林育賢。(2006) 從神經膠原致癌基因著手邁向標靶癌症治療的新境界。中國醫訊40 November王伯徹、陳啟楨、華傑。(1998) 食藥用菇類的培養與應用。食品工業發展研究所。p.144-150。
江素瑛、吳焜裕、王秋萍、魏逸傑、施睿宏、高尚德以及謝慶良。(2002)樟芝之致基因毒性與抗基因毒性評估。台灣保健食品協會，第二屆第二次年會，大會議程及論文摘要。
江素瑛。(2001)靈芝與樟芝之安全與毒理。「保健食品」跨部會整合推動委員會 p. 64-72。
呂鋒洲。 (2002)牛樟芝各抗腫瘤有效成分的分離、純化，誘發腫瘤凋亡及其作用機轉的研究。十一年度保健食品研究開發計畫成果發表會。p.13-16。
沈立言。(2000)牛樟芝菌絲體發酵萃取液對肝臟生理機能性之影響89年度保健食品研究開發計畫心得發表會。 p.191-198。
李炫璋、莊正宏、蔡金川、黃仕政、陳勁初以及胡淼琳。(2002)中華民國食品科學技術學會。第三十二次(第十六屆第二次)會員大會手冊。 p. 339。
林文鑫、陳俊憲、陳勁初以及呂鋒州。(2000)樟芝液態發酵萃取物對腫瘤細胞株之毒殺性分析。 中華民國食品科學技術學會 第三十次(第十五屆第二次)會員大會手冊。
吳德鵬。 (1995) 樟芝微量成分的研究。國立台灣師範大學化學研究所碩士論文。郭淑卿。(2002) 樟芝發酵液對大鼠肝臟纖維化及胃腸功能之改善作用。中國藥學研究所，碩士論文。陳勁初、林文鑫、陳清農、許勝潔、黃仕政、陳炎煉。(2001)台灣特有真菌-樟芝。
陳啟豪。(2004) 分析雌激素對SKOV3卵巢癌細胞株移行與侵襲能力之抑制作用。國立臺灣大學醫學院臨床醫學研究所，碩士論文。張中姿、陳俊憲、林文鑫、陳勁初以及呂鋒洲。(2001)中華民國食品科學技術學會。第三十二次 (第十六屆第一次)會員大會手冊。 p. 265。
黃鈴娟。 (2000)樟芝與姬松茸之抗氧化性質及其多醣組成分析。國立中興大學食品學系，碩士論文。簡秋源、姜宏哲以及陳淑貞。(1997)牛樟菇培養性狀及其三萜類成分分析之研究，牛樟生物學及育林技術研討會論文集。林業叢刊第72 號：133-137。
劉翠玲。(2002)樟芝對倉鼠體內脂質代謝與抗氧化狀態之影響。輔仁大學食品營養學系研究所，碩士論文。戴宇昀。(2001)樟芝菌絲體與子實體對四氯化碳及酒精誘導之慢性及急性肝損傷之保肝功能評估. 國立中興大學食品科學系研究所，碩士論文。黃依婷。(2009)樟芝抑制人類乳癌細胞轉移作用及機制探討。中國醫
藥大學營養學系碩士班，碩士論文。